Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

April 30, 2014

Conditions
Carcinoma, Basal Cell (BCC)
Interventions
DRUG

Treatment with BSCT

"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

TKL Research, Inc.

INDUSTRY

lead

Biosceptre

INDUSTRY

NCT02587819 - Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment | Biotech Hunter | Biotech Hunter